Skip to product information
1 of 1

Tau (phospho T217) Recombinant Rabbit mAb (SDT-R205-TT217-4)

Tau (phospho T217) Recombinant Rabbit mAb (SDT-R205-TT217-4)

Catalog Number: S0B3173 Application: ELISA Reactivity: Human,Mouse Conjugation: Unconjugated Brand: Starter
Price:
Regular price $835.00 USD
Regular price Sale price $835.00 USD
Size:
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Rabbit
Antigen Tau (phospho T217)
Synonyms p-Tau217, phospho T217
Immunogen Synthetic Peptide
Accession P10636
Clone Number SDT-R205-TT217-4
Antibody Type Recombinant mAb
Isotype IgG
Application Sandwich ELISA
Reactivity Hu, Ms
Predicted Reactivity Mouse
Cross Reactivity Does not recognize total Tau
Purification Protein A
Concentration 2 mg/ml
Purity >95% by HPLC
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer PBS pH7.4, 0.03% Proclin 300
Stability & Storage

12 months from date of receipt, 2 to 8 °C as supplied

Dilution


application dilution species
Sandwich ELISA N/A

Background

Blood-based biomarkers for Alzheimer’s disease that detect beta-amyloid (Aβ) and phosphorylated tau (pTau) proteinopathy are rapidly developing. The utility and convenience of an accurate blood test has clear implications for accelerating and improving clinical research and practice. Several candidate markers exist including mass spectrometry and immunoassay measured Aβ42 and Aβ40 and their ratio and phosphorylated tau at threonine 217 (pTau217), 181 (pTau181), and other phosphorylated sites, as well as non-specific markers of neurodegeneration and astrogliosis, including neurofilament light (NfL) and glial fibrillary acidic protein (GFAP). Tau is a microtubule-associated protein important for neuronal stability. One of the major neuropathological hallmarks of Alzheimer’s disease (AD) is the hyperphosphorylation of the tau protein which is thought to lead to pathological tau spread and neuronal death. Recent, research studies have shown that plasma levels of p-Tau 217 are elevated in AD patients. Additionally, it has been demonstrated that plasma p-Tau 217 levels are increased in the early stages of the AD continuum and are correlated with amyloid-PET positivity. These findings suggest that p-Tau 217 may serve as a promising blood-based biomarker to aid in AD research, drug development, diagnosis, disease monitoring and patient care. Recently, interest has turned to pTau217, as cerebrospinal fluid levels increase early in autosomal dominant Alzheimer’s disease and better discriminate Alzheimer’s disease from non-Alzheimer’s subgroups of cognitively impaired adults, compared to pTau181. In plasma, pTau217 accurately differentiates persons with neuropathologically defined Alzheimer’s disease from other dementia. Further, in vivo plasma pTau217 levels correlate with ex vivo protein levels and spatial burden in post-mortem brain tissue. Next, plasma pTau217 levels discriminate diagnostic groups informed by amyloid PET. pTau217 levels are elevated among impaired (Alzheimer’s disease or mild cognitive impairment (MCI)) Aβ+ participants compared to cognitively unimpaired (CU) Aβ− participants, and plasma pTau217 and tau PET signal show moderate to high agreement. Serial plasma pTau217 levels also differentiate Alzheimer’s disease from non-Alzheimer’s MCI, remaining stable and non-elevated in Aβ− patients and increasing over time in Aβ+ patients. These findings suggest that p-Tau 217 may serve as a promising blood-based biomarker to aid in AD research, drug development, diagnosis, disease monitoring and patient care.

Picture

Paired Recommendations

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)